Evotec SE EVO

What this company does

Evotec SE provides preclinical research and development services spanning Discovery Services, Development and Manufacturing Services, and ADME-Tox Solutions, and covers the value chain of discovery, process development and manufacturing in biologics through its Just – Evotec Biologics business. As of December 31, 2025, its workforce included 3,682 scientific experts across a broad range of disciplines along the R&D value chain. At the start of 2025, the company operated 15 sites, including a network of five manufacturing facilities such as the J.POD continuous biologics manufacturing facility in Redmond, Washington, API manufacturing capabilities in Abingdon, UK, and Verona, Italy, and a GMP manufacturing site for advanced therapy medicinal products in Medolla, Italy, and its local footprint represented 14 sites at the end of 2025. Evotec reports the results of its work and collaborations with third parties through two reporting segments, Just – Evotec Biologics and Discovery & Preclinical Development. Just – Evotec Biologics is the company's approach to discovering, optimizing, developing and manufacturing bio-therapeutics, providing services in antibody molecular optimization, product and process design, and single-use, perfusion-based continuous bioprocessing platforms covering both early-stage and commercial biomanufacturing. The Discovery & Preclinical Development segment primarily includes drug discovery and preclinical development services and solutions, beginning with sourcing novel treatment ideas derived from patient data and continuing through target validation and lead optimization, with revenue generated through the Evotec and Cyprotex brands.

Written from the business description in Evotec SE's annual report to the U.S. Securities and Exchange Commission, filed 8 April 2026. Every sentence was checked against that document before publication.